Three-Year Outcome of Sirolimus-Eluting Versus Bare-Metal Stents for the Treatment of ST-Segment Elevation Myocardial Infarction (from the MISSION! Intervention Study)

American Journal of Cardiology

Volumn 106, Issue 1, 2010, Pages 4-12

  Atary, Jael Z ^a   van der Hoeven, Bas L ^a   Liem, Su San ^a   Jukema, J Wouter ^a   van der Bom, Johanna G ^a   Atsma, Douwe E ^a   Bootsma, Marianne ^a   Zeppenfeld, Katja ^a   van der Wall, Ernst E ^a   Schalij, Martin J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RAPAMYCIN;

ADULT; ANGIOGRAPHY; ARTICLE; BARE METAL STENT; BLOOD VESSEL DIAMETER; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; SAFETY; SINGLE BLIND PROCEDURE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; DRUG-ELUTING STENTS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77953611442     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.02.005     Document Type: Article

References (24)

1. van der Hoeven B.L., Liem S.S., Jukema J.W., Suraphakdee N., Putter H., Dijkstra J., Atsma D.E., Bootsma M., Zeppenfeld K., Oemrawsingh P.V., van der Wall E.E., and Schalij M.J. Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. J Am Coll Cardiol 51 (2008) 618-626
2. Liem S.S., van der Hoeven B.L., Oemrawsingh P.V., Bax J.J., van der Bom J.G., Bosch J., Viergever E.P., van Rees C., Padmos I., Sedney M.I., van Exel H.J., Verwey H.F., Atsma D.E., van der Velde E.T., Jukema J.W., van der Wall E.E., and Schalij M.J. MISSION!: optimization of acute and chronic care for patients with acute myocardial infarction. Am Heart J 153 (2007) 14-11
3. Alpert J.S., Thygesen K., Antman E., and Bassand J.P. Myocardial infarction redefined-a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 36 (2000) 959-969
4. Apple F.S., Wu A.H., and Jaffe A.S. European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials. Am Heart J 144 (2002) 981-986
5. Cutlip D.E., Windecker S., Mehran R., Boam A., Cohen D.J., van Es G.A., Steg P.G., Morel M.A., Mauri L., Vranckx P., McFadden E., Lansky A., Hamon M., Krucoff M.W., and Serruys P.W. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
6. Bavry A.A., Kumbhani D.J., Quiroz R., Ramchandani S.R., Kenchaiah S., and Antman E.M. Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non-ST-segment elevation acute coronary syndromes: a meta-analysis and review of the literature. Am J Cardiol 93 (2004) 830-835
7. Keeley E.C., Boura J.A., and Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361 (2003) 13-20
8. Mehta S.R., Cannon C.P., Fox K.A., Wallentin L., Boden W.E., Spacek R., Widimsky P., McCullough P.A., Hunt D., Braunwald E., and Yusuf S. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 293 (2005) 2908-2917
9. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., Caputo R.P., Kereiakes D.J., Williams D.O., Teirstein P.S., Jaeger J.L., and Kuntz R.E. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
10. Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J.T., Turco M., Caputo R., Bergin P., Greenberg J., Popma J.J., and Russell M.E. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
11. Lemos P.A., Saia F., Hofma S.H., Daemen J., Ong A.T., Arampatzis C.A., Hoye A., McFadden E., Sianos G., Smits P.C., van der Giessen W.J., de F.P., van Domburg R.T., and Serruys P.W. Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol 43 (2004) 704-708
12. Slottow T.L., Steinberg D.H., Roy P., Javaid A., Buch A.N., Okabe T., Xue Z., Smith K., Torguson R., Pichard A.D., Satler L.F., Suddath W.O., Kent K.M., and Waksman R. Drug-eluting stents are associated with similar cardiovascular outcomes when compared to bare metal stents in the setting of acute myocardial infarction. Cardiovasc Revasc Med 9 (2008) 24-28
13. Steg P.G., Fox K.A., Eagle K.A., Furman M., Van de W.F., Montalescot G., Goodman S.G., Avezum A., Huang W., and Gore J.M. Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. Eur Heart J 30 (2009) 321-329
14. Mauri L., Silbaugh T.S., Garg P., Wolf R.E., Zelevinsky K., Lovett A., Varma M.R., Zhou Z., and Normand S.L. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med 359 (2008) 1330-1342
15. Stone G.W., Lansky A.J., Pocock S.J., Gersh B.J., Dangas G., Wong S.C., Witzenbichler B., Guagliumi G., Peruga J.Z., Brodie B.R., Dudek D., Mockel M., Ochala A., Kellock A., Parise H., and Mehran R. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 360 (2009) 1946-1959
16. Laarman G.J., Suttorp M.J., Dirksen M.T., van H.L., Kiemeneij F., Slagboom T., van der Wieken L.R., Tijssen J.G., Rensing B.J., and Patterson M. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 355 (2006) 1105-1113
17. Menichelli M., Parma A., Pucci E., Fiorilli R., De F.F., Nazzaro M., Giulivi A., Alborino D., Azzellino A., and Violini R. Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). J Am Coll Cardiol 49 (2007) 1924-1930
18. Spaulding C., Henry P., Teiger E., Beatt K., Bramucci E., Carrie D., Slama M.S., Merkely B., Erglis A., Margheri M., Varenne O., Cebrian A., Stoll H.P., Snead D.B., and Bode C. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355 (2006) 1093-1104
19. Kastrati A., Dibra A., Spaulding C., Laarman G.J., Menichelli M., Valgimigli M., Di L.E., Kaiser C., Tierala I., Mehilli J., Seyfarth M., Varenne O., Dirksen M.T., Percoco G., Varricchio A., Pittl U., Syvanne M., Suttorp M.J., Violini R., and Schomig A. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 28 (2007) 2706-2713
20. Valgimigli M., Percoco G., Malagutti P., Campo G., Ferrari F., Barbieri D., Cicchitelli G., McFadden E.P., Merlini F., Ansani L., Guardigli G., Bettini A., Parrinello G., Boersma E., and Ferrari R. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 293 (2005) 2109-2117
21. Di Lorenzo E., Sauro R., Varricchio A., Carbone G., Cortese G., Capasso M., Lanzillo T., Manganelli F., Mariello C., Siano F., Pagliuca M.R., Stanco G., Rosato G., and De Luca G. Long-term outcome of drug-eluting stents compared with bare metal stents in st-segment elevation myocardial infarction. Results of the Paclitaxel- or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty (PASEO) randomized trial. Circulation 120 (2009) 964-972
22. Applegate R.J., Sacrinty M.T., Kutcher M.A., Santos R.M., Gandhi S.K., and Little W.C. 3-year comparison of drug-eluting versus bare-metal stents. JACC Cardiovasc Interv 2 (2009) 231-239
23. Pfisterer M., Brunner-La Rocca H.P., Rickenbacher P., Hunziker P., Mueller C., Nietlispach F., Leibundgut G., Bader F., and Kaiser C. Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter?. Three-year follow-up of BASKET. Eur Heart J 30 (2009) 16-24
24. Daemen J., Tanimoto S., Garcia-Garcia H.M., Kukreja N., van de S.M., Sianos G., de Jaegere P.P., van Domburg R.T., and Serruys P.W. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH registries). Am J Cardiol 99 (2007) 1027-1032